Posts

Showing posts with the label ezetimibe

aggressive LDL lowering and coronary plaque regression modified

Image
  A new study confirmed that very intensive lipid-lowering led to atherosclerotic plaque regression in patients who had not been on statins previously: see statin intensive plaque regression JAMANetwork2026 in dropbox, or doi:10.1001/jamacardio.2026.4788 Details: --this study was a prespecified analysis of the FLOWPROMOTE study, a randomized clinical trial performed in 3 Danish hospitals that had significant experience in conducting coronary CTA (coronary computed tomography angiography) as well as FFR-CT (flow fractional reserve)     -- individuals were eligible to be included if they had coronary CTA >50% and FFR-CT <0.8 and had not been on chronic statins     -- the initial coronary CTA at the time of diagnosis by was repeated at 9 and 18 months     -- the goal of this study was to assess the association between achieved LDL cholesterol levels and atherosclerotic plaque regression     -- this study was done from May 2020 to Oc...

high Lp(a) increases risk of recurrent ASCVD

  A recent study found that in patients with atherosclerotic cardiovascular disease (ASCVD), there was a progressive increase in recurrent cardiac events as lipoprotein(a) levels increased: see   Lp(a) recurrent ASCVD EuropHeartJ 2025  in dropbox. or   doi.org/10.1093/eurheartj/ehaf297 )   Details : -- they accessed the Family Heart Database of US medical claims from 340 million adults between 2012-2022, representing at least 1/2 of the national census population, with lipid data available for about 1/3 of them -- these medical claims included medication use, diagnoses, procedures, and surgeries     -- 273,770 people had diagnosed ASCVD as well as lipoprotein(a) levels, also referred to as Lp(a), measured         -- ASCVD was defined as: evidence of an MI, other acute coronary syndromes, percutaneous coronary interventions (PCI), CABG, stable angina, ischemic stroke, other cerebral vascular disease, TIA, peripheral va...